535 related articles for article (PubMed ID: 31149033)
1. Preclinical efficacy of hK2 targeted [
Timmermand OV; Elgqvist J; Beattie KA; Örbom A; Larsson E; Eriksson SE; Thorek DLJ; Beattie BJ; Tran TA; Ulmert D; Strand SE
Theranostics; 2019; 9(8):2129-2142. PubMed ID: 31149033
[TBL] [Abstract][Full Text] [Related]
2. Genetic signature of prostate cancer mouse models resistant to optimized hK2 targeted α-particle therapy.
Bicak M; Lückerath K; Kalidindi T; Phelps ME; Strand SE; Morris MJ; Radu CG; Damoiseaux R; Peltola MT; Peekhaus N; Ho A; Veach D; Malmborg Hager AC; Larson SM; Lilja H; McDevitt MR; Klein RJ; Ulmert D
Proc Natl Acad Sci U S A; 2020 Jun; 117(26):15172-15181. PubMed ID: 32532924
[TBL] [Abstract][Full Text] [Related]
3. Panitumumab Modified with Metal-Chelating Polymers (MCP) Complexed to
Aghevlian S; Lu Y; Winnik MA; Hedley DW; Reilly RM
Mol Pharm; 2018 Mar; 15(3):1150-1159. PubMed ID: 29314858
[TBL] [Abstract][Full Text] [Related]
4. Towards Personalized Treatment of Prostate Cancer: PSMA I&T, a Promising Prostate-Specific Membrane Antigen-Targeted Theranostic Agent.
Chatalic KL; Heskamp S; Konijnenberg M; Molkenboer-Kuenen JD; Franssen GM; Clahsen-van Groningen MC; Schottelius M; Wester HJ; van Weerden WM; Boerman OC; de Jong M
Theranostics; 2016; 6(6):849-61. PubMed ID: 27162555
[TBL] [Abstract][Full Text] [Related]
5. Feed-forward alpha particle radiotherapy ablates androgen receptor-addicted prostate cancer.
McDevitt MR; Thorek DLJ; Hashimoto T; Gondo T; Veach DR; Sharma SK; Kalidindi TM; Abou DS; Watson PA; Beattie BJ; Timmermand OV; Strand SE; Lewis JS; Scardino PT; Scher HI; Lilja H; Larson SM; Ulmert D
Nat Commun; 2018 Apr; 9(1):1629. PubMed ID: 29691406
[TBL] [Abstract][Full Text] [Related]
6. Enhancing Treatment Efficacy of
Kuo HT; Merkens H; Zhang Z; Uribe CF; Lau J; Zhang C; Colpo N; Lin KS; Bénard F
Mol Pharm; 2018 Nov; 15(11):5183-5191. PubMed ID: 30251544
[TBL] [Abstract][Full Text] [Related]
7. Intratherapeutic biokinetic measurements, dosimetry parameter estimates, and monitoring of treatment efficacy using cerenkov luminescence imaging in preclinical radionuclide therapy.
Timmermand OV; Tran TA; Strand SE; Axelsson J
J Nucl Med; 2015 Mar; 56(3):444-9. PubMed ID: 25655628
[TBL] [Abstract][Full Text] [Related]
8. Theranostic pretargeted radioimmunotherapy of internalizing solid tumor antigens in human tumor xenografts in mice: Curative treatment of HER2-positive breast carcinoma.
Cheal SM; Xu H; Guo HF; Patel M; Punzalan B; Fung EK; Lee SG; Bell M; Singh M; Jungbluth AA; Zanzonico PB; Piersigilli A; Larson SM; Cheung NV
Theranostics; 2018; 8(18):5106-5125. PubMed ID: 30429889
[TBL] [Abstract][Full Text] [Related]
9. High resolution digital autoradiographic and dosimetric analysis of heterogeneous radioactivity distribution in xenografted prostate tumors.
Timmermand OV; Nilsson J; Strand SE; Elgqvist J
Med Phys; 2016 Dec; 43(12):6632. PubMed ID: 27908170
[TBL] [Abstract][Full Text] [Related]
10. Voxel-Based Dosimetry of Iron Oxide Nanoparticle-Conjugated
Gupta A; Shin JH; Lee MS; Park JY; Kim K; Kim JH; Suh M; Park CR; Kim YJ; Song MG; Jeong JM; Lee DS; Lee YS; Lee JS
Mol Pharm; 2019 Apr; 16(4):1498-1506. PubMed ID: 30821463
[TBL] [Abstract][Full Text] [Related]
11. Preclinical Dosimetry, Imaging, and Targeted Radionuclide Therapy Studies of Lu-177-Labeled Albumin-Binding, PSMA-Targeted CTT1403.
Ling X; Latoche JD; Choy CJ; Kurland BF; Laymon CM; Wu Y; Salamacha N; Shen D; Geruntho JJ; Rigatti LH; Windish HP; Langton-Webster B; Berkman CE; Anderson CJ
Mol Imaging Biol; 2020 Apr; 22(2):274-284. PubMed ID: 31321650
[TBL] [Abstract][Full Text] [Related]
12. Albumin-Binding PSMA Ligands: Optimization of the Tissue Distribution Profile.
Benešová M; Umbricht CA; Schibli R; Müller C
Mol Pharm; 2018 Mar; 15(3):934-946. PubMed ID: 29400475
[TBL] [Abstract][Full Text] [Related]
13. Intratumorally Injected 177Lu-Labeled Gold Nanoparticles: Gold Nanoseed Brachytherapy with Application for Neoadjuvant Treatment of Locally Advanced Breast Cancer.
Yook S; Cai Z; Lu Y; Winnik MA; Pignol JP; Reilly RM
J Nucl Med; 2016 Jun; 57(6):936-42. PubMed ID: 26848176
[TBL] [Abstract][Full Text] [Related]
14. Mechanisms of Cell Killing Response from Low Linear Energy Transfer (LET) Radiation Originating from (177)Lu Radioimmunotherapy Targeting Disseminated Intraperitoneal Tumor Xenografts.
Yong KJ; Milenic DE; Baidoo KE; Brechbiel MW
Int J Mol Sci; 2016 May; 17(5):. PubMed ID: 27196891
[TBL] [Abstract][Full Text] [Related]
15. Curative Multicycle Radioimmunotherapy Monitored by Quantitative SPECT/CT-Based Theranostics, Using Bispecific Antibody Pretargeting Strategy in Colorectal Cancer.
Cheal SM; Fung EK; Patel M; Xu H; Guo HF; Zanzonico PB; Monette S; Wittrup KD; Cheung NV; Larson SM
J Nucl Med; 2017 Nov; 58(11):1735-1742. PubMed ID: 28705917
[TBL] [Abstract][Full Text] [Related]
16. Biodistributions of 177Lu- and 111In-labeled 7E11 antibodies to prostate-specific membrane antigen in xenograft model of prostate cancer and potential use of 111In-7E11 as a pre-therapeutic agent for 177Lu-7E11 radioimmunotherapy.
Pan MH; Gao DW; Feng J; He J; Seo Y; Tedesco J; Wolodzko JG; Hasegawa BH; Franc BL
Mol Imaging Biol; 2009; 11(3):159-66. PubMed ID: 19034582
[TBL] [Abstract][Full Text] [Related]
17. Harnessing Androgen Receptor Pathway Activation for Targeted Alpha Particle Radioimmunotherapy of Breast Cancer.
Thorek DLJ; Ku AT; Mitsiades N; Veach D; Watson PA; Metha D; Strand SE; Sharma SK; Lewis JS; Abou DS; Lilja HG; Larson SM; McDevitt MR; Ulmert D
Clin Cancer Res; 2019 Jan; 25(2):881-891. PubMed ID: 30254080
[TBL] [Abstract][Full Text] [Related]
18. Dosimetry of
Violet J; Jackson P; Ferdinandus J; Sandhu S; Akhurst T; Iravani A; Kong G; Kumar AR; Thang SP; Eu P; Scalzo M; Murphy D; Williams S; Hicks RJ; Hofman MS
J Nucl Med; 2019 Apr; 60(4):517-523. PubMed ID: 30291192
[No Abstract] [Full Text] [Related]
19. Dual-Receptor-Targeted Radioimmunotherapy of Human Breast Cancer Xenografts in Athymic Mice Coexpressing HER2 and EGFR Using 177Lu- or 111In-Labeled Bispecific Radioimmunoconjugates.
Razumienko EJ; Chen JC; Cai Z; Chan C; Reilly RM
J Nucl Med; 2016 Mar; 57(3):444-52. PubMed ID: 26429962
[TBL] [Abstract][Full Text] [Related]
20.
Kristiansson A; Örbom A; Ahlstedt J; Karlsson H; Zedan W; Gram M; Åkerström B; Strand SE; Altai M; Strand J; Vilhelmsson Timmermand O
Biomolecules; 2021 Feb; 11(2):. PubMed ID: 33579037
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
